TG Therapeutics(DE:NKB2)
€58.80+9.10 (+13.95%)
DE:NKB2
TG Therapeutics Revenue
€58.80
At close:+9.10 (+13.95%)
TG Therapeutics (NKB2) Revenue
3 Followers
TG Therapeutics Revenue
TG Therapeutics had a revenue of 259.94M in the quarter ending Sep 30, 2026, with 8.16%. This bring the company's revenue in the last twelve months to 897.76M, Increased 12.29%. In the fiscal year ending Dec 31, 2025, TG Therapeutics had annual revenue of 616.29M with 87.32% growth.
- Revenue (ttm)
- 897.76M
- Revenue Growth
- 61.37%
- P/S Ratio
- 14.20
- Revenue/Employee
- EUR 1,544,579
- Employees
- 399
- Market Cap
- EUR 8.75B
Revenue Chart
TG Therapeutics Revenue - Annual
Revenue History
| Fiscal End Date | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 616.29M | 287.28M | 87.32% |
| Dec 31, 2024 | 329.00M | 95.34M | 40.80% |
| Dec 31, 2023 | 233.66M | 230.88M | 8290.02% |
| Dec 31, 2022 | 2.79M | -3.90M | -58.36% |
| Dec 31, 2021 | 6.69M | 6.54M | 4300.66% |
| Dec 31, 2020 | 152.00K | 0.00 | 0.00% |
| Dec 31, 2019 | 152.00K | 0.00 | 0.00% |
| Dec 31, 2018 | 152.00K | -381.00 | -0.25% |
| Dec 31, 2017 | 152.38K | ― | ― |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.